Niconovum
Niconovum AB, a Malmö-based British American Tobacco subsidiary, develops and sells regulated, 100% tobacco-free Nicotine Replacement Therapy products (Zonnic Pouch, Mouth Spray, Lozenge) to adult consumers in the Nordics and through UK private label manufacturing.
- Company typePrivate
- Founded2000
- HeadquartersMalmö, Sweden
- Headcount11–50
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Niconovum does
Niconovum AB is a Sweden-based specialty pharmaceutical company that develops and sells Nicotine Replacement Therapy (NRT) products under the Zonnic brand, targeting adults who want to quit or reduce their tobacco consumption. Founded in 2000 by Dr. Karl Olof Fagerström, a recognized authority on smoking cessation, the company was acquired by Reynolds American Inc. in 2009 and became a wholly-owned British American Tobacco subsidiary in 2017 following BAT's acquisition of RAI. Niconovum is headquartered in Malmö, Sweden, and operates with 11-50 employees.
The company's product portfolio consists of three 100% tobacco-free, regulated-medicine NRT formats: Zonnic Pouch, Zonnic Mouth Spray, and Zonnic Lozenge. Each format is offered in multiple strengths and is approved by relevant Medical Agencies based on safety, efficacy, and manufacturing processes. Manufacturing is performed by audited and licensed medical facilities in Sweden and France, and the products are positioned to deliver fast and long-lasting relief from nicotine cravings and withdrawal symptoms. There is no evidence in the input of proprietary software, AI/ML, or digital health components; the differentiators are clinical and regulatory rather than technological.
Niconovum generates revenue through three streams: branded Zonnic retail and e-commerce sales across four Nordic countries (Sweden, Norway, Finland, Iceland) via regional websites and physical retail; B2B private label NRT manufacturing for a major UK retailer; and licensing and in-licensing of NRT products and technology globally. The company pursues a direct-to-consumer and B2B model rather than platform or subscription economics, with no publicly disclosed pricing. As a wholly-owned BAT subsidiary, Niconovum functions as a strategic business unit within the parent's harm reduction portfolio rather than as an independent growth-stage company.
Niconovum firmographics
Firmographics- Name
- Niconovum
- Legal name
- Niconovum AB
- Website
- https://niconovum.se
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Niconovum AB, a Malmö-based British American Tobacco subsidiary, develops and sells regulated, 100% tobacco-free Nicotine Replacement Therapy products (Zonnic Pouch, Mouth Spray, Lozenge) to adult consumers in the Nordics and through UK private label manufacturing.
- Ownership category
- akta.pro rank
Niconovum industry classification
Industry- Product category
- Nicotine Replacement Therapy (NRT) / Smoking Cessation Products
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro industry
- Smoking Cessation & Nicotine Replacement Therapy (Gum, Patches, Lozenges)Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)Nicotine Pouches (Tobacco-Free) Manufacturing & BrandsConsumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Tobacco & Nicotine Products Manufacturing & BrandsSmoking Cessation & Nicotine Replacement Therapy (NRT)Tobacco & Nicotine Contract Manufacturing & Private LabelConsumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Tobacco & Nicotine Products Manufacturing & Brands
Keywords
Where Niconovum is headquartered
LocationHeadquarters
- HQ city
- Malmö
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Niconovum business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Zonnic Brand Product Sales: Direct consumer sales of branded NRT products (Zonnic Pouch, Mouth Spray, Lozenge) across Nordic markets (Sweden, Norway, Finland, Iceland) through retail channels and regional websites.
- Private Label Manufacturing: Manufactures private label NRT products for a major retailer in the UK, providing B2B revenue through contract manufacturing arrangements.
- Licensing and In-licensing: Pursues both out-licensing and in-licensing opportunities for NRT products and technology, generating revenue through intellectual property arrangements.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels3 records
Niconovum product offering
Product offeringCore offering
Niconovum develops, manufactures, and sells 100% tobacco-free Nicotine Replacement Therapy (NRT) products under the Zonnic brand in three delivery formats: Zonnic Pouch, Zonnic Mouth Spray, and Zonnic Lozenge. The company sells directly to consumers through retail/pharmacy channels and regional Zonnic e-commerce sites in Sweden, Norway, Finland, and Iceland, and also operates B2B private label contract manufacturing for a major UK retailer alongside out-licensing and in-licensing activities for NRT products and technology.
Product overview
Niconovum offers a unified portfolio of Nicotine Replacement Therapy (NRT) products under the Zonnic brand name. The portfolio consists of three distinct product formats—Zonnic Pouch, Zonnic Mouth Spray, and Zonnic Lozenge—all designed as 100% tobacco-free, regulated medical devices. These products provide consumers with options to meet personal tobacco reduction goals by delivering efficient and pleasant nicotine delivery. The company sells directly under the Zonnic brand across Sweden, Norway, Finland, and Iceland, while also manufacturing private-label NRT products for major UK retailers.
Differentiator
Problem solved
Functional benefit
Brands
- Zonnic: Zonnic is the brand name for Niconovum's Nicotine Replacement Therapy products including Zonnic Pouch, Zonnic Mouth Spray, and Zonnic Lozenge. Products are 100% tobacco free and regulated medicines approved by Medical Agencies.
Products and services
- Zonnic Pouch A 100% tobacco-free nicotine pouch product that provides fast and long-lasting nicotine craving relief for adults over 18 looking to quit or reduce tobacco consumption. Sold as a regulated NRT medicine under the Zonnic brand across Nordic markets.
- Zonnic Mouth Spray A 100% tobacco-free fast-acting mouth spray nicotine replacement therapy that delivers rapid nicotine craving relief for adults over 18 looking to quit or reduce tobacco consumption. Sold as a regulated NRT medicine under the Zonnic brand across Nordic markets.
- Zonnic Lozenge A 100% tobacco-free lozenge nicotine replacement therapy product offering convenient and long-lasting nicotine craving relief in multiple strength options for adults over 18. Sold as a regulated NRT medicine under the Zonnic brand across Nordic markets.
- Private Label NRT Manufacturing B2B contract manufacturing of a private label Nicotine Replacement Therapy product for a major retailer in the UK. Produced by audited and licensed medical manufacturers in Sweden and France in compliance with regulatory standards.
- NRT Product and Technology Licensing Out-licensing and in-licensing of Nicotine Replacement Therapy products and proprietary delivery technology to global partners, generating revenue through intellectual property arrangements.
Companies that use Niconovum
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles3 records
Niconovum technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Niconovum partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Major UK RetailercoreNiconovum manufactures a private label NRT product for a major retailer in the UK, serving as a B2B manufacturing partner.
- Swedish and French Medical ManufacturerscoreAll Zonnic products are produced by audited and licensed medical manufacturers in Sweden and France, ensuring compliance with regulatory standards for medicinal products.
Scale indicators3 records
Recent moves8 records
Expansion highlights4 records
Niconovum competitors and assessment
Company assessmentDirect peers
- Haleon: Owner of the Nicorette and NicoDerm CQ brands, Haleon is the global category leader in NRT and the most direct competitor to Niconovum's Zonnic portfolio, with overlapping regulated NRT products sold across multiple geographies.
- Perrigo Company: A leading private label manufacturer of OTC NRT products for retailers in the US and Europe. Directly comparable to Niconovum on the B2B private label manufacturing side of the business, serving similar retailer customers.
- Fertin Pharma: A Danish contract manufacturer specializing in nicotine gum and other medicated chewing gum formats. Highly comparable to Niconovum on the B2B manufacturing side, serving similar pharma and consumer health customers in Europe.
Broad incumbents
- Johnson & Johnson Consumer Health: Markets the Nicotinell NRT brand and operates a broad consumer health portfolio. Overlaps with Niconovum in regulated NRT (gum, patch, lozenge) and competes for the same consumer health retail and pharmacy shelf space.
- Philip Morris International (Swedish Match): Owns Swedish Match and the Zyn tobacco-free nicotine pouch brand. Competes in the same tobacco-free pouch category as Zonnic Pouch, though Zyn is positioned as a recreational product rather than a regulated NRT medicine.
- Imperial Brands: Markets nicotine pouches (Skruf, ZoneX) and other modern oral nicotine products. Overlaps with Niconovum's Zonnic Pouch on format and consumer, though differentiated by regulatory classification.
- Japan Tobacco International: Markets the Nordic Spirit tobacco-free nicotine pouch brand. A relevant adjacent competitor to Zonnic Pouch in the Nordic region, where Niconovum's core market overlaps with JTI's strongest pouch geography.
Emerging players
- Dr. Reddy's Laboratories: Manufactures and sells generic OTC NRT products (gum, lozenge) across multiple markets. Comparable to Niconovum in regulated NRT manufacturing capability and category focus, with greater geographic reach but less brand-led positioning.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Niconovum social profiles
Digital presenceNiconovum financial estimates
Financial estimateRevenue estimate
Valuation estimate
Niconovum leadership team
Management profileNumber of profiles
Profiles1 record
Niconovum funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Niconovum M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Niconovum
What does Niconovum do?
Niconovum develops, manufactures, and sells 100% tobacco-free Nicotine Replacement Therapy (NRT) products under the Zonnic brand in three delivery formats: Zonnic Pouch, Zonnic Mouth Spray, and Zonnic Lozenge. The company sells directly to consumers through retail/pharmacy channels and regional Zonnic e-commerce sites in Sweden, Norway, Finland, and Iceland, and also operates B2B private label contract manufacturing for a major UK retailer alongside out-licensing and in-licensing activities for NRT products and technology.
Is Niconovum a public or private company?
Niconovum is a private company. It is classified as corporate owned and is currently operating.
When was Niconovum founded?
Niconovum was founded in 2000. It employs 11 to 50 people.
Where is Niconovum based?
Niconovum is headquartered in Malmö, Sweden, in the Europe region.
How does Niconovum make money?
Three revenue lines are on record. Zonnic Brand Product Sales are the primary driver. The others are private Label Manufacturing and licensing and In-licensing.
Who are Niconovum's main competitors?
Direct peers on record are Haleon, Perrigo Company and Fertin Pharma. Broad incumbents are Johnson & Johnson Consumer Health, Philip Morris International (Swedish Match), Imperial Brands and Japan Tobacco International. Dr. Reddy's Laboratories is listed as an emerging player.
Does Niconovum have an API?
No public API is recorded for Niconovum.
What industry is Niconovum in?
Niconovum's product category is Nicotine Replacement Therapy (NRT) / Smoking Cessation Products. Its primary akta.pro industry code is CRADAMAI, Smoking Cessation & Nicotine Replacement Therapy (Gum, Patches, Lozenges), with a secondary code of CRADAJAI, Nicotine Pouches (Tobacco-Free) Manufacturing & Brands. Its NAICS code is 32541 and its SIC code is 2834.